# Catheter-Based Valvular and Structural Interventions in Cancer Patients

**Authors:** Tony Joudi, Ahmad Safdar, Neehal Shukla, Rochell Issa, Zoha Majeed, Alok A. Khorana, Cezar Illescu, Rishi Puri, Rohit Moudgil

PMC · DOI: 10.1007/s11886-026-02351-x · Current Cardiology Reports · 2026-03-04

## TL;DR

This paper reviews how minimally invasive heart procedures can safely treat cancer patients with heart issues, offering faster recovery and fewer complications.

## Contribution

The paper highlights the safety and effectiveness of catheter-based heart interventions in cancer patients, emphasizing tailored care.

## Key findings

- Catheter-based interventions show comparable short-term outcomes in cancer and non-cancer patients.
- Procedural complications and bleeding risks are lower with these minimally invasive approaches.
- Long-term survival is influenced by cancer type, requiring careful patient selection and antithrombotic management.

## Abstract

This review examines the evolving role of catheter‐based valvular and structural interventions in cancer patients. We sought to answer whether minimally invasive approaches, including transcatheter aortic valve replacement, mitral valve repair, left atrial appendage occlusion, and patent foramen ovale closure, provide safe and effective treatments in high‐risk oncologic populations.

Emerging research indicates that these interventions yield comparable short‐term outcomes in cancer and non‐cancer patients, with reduced procedural complications, lower bleeding risks, and improved recovery times. Studies also suggest that careful patient selection and tailored antithrombotic management are critical, as long‐term survival is affected by the underlying malignancy.

Our review concludes that catheter‐based interventions offer significant benefits in managing cardiovascular complications in cancer patients. Future investigations should focus on refining selection criteria, optimizing perioperative care, and evaluating long‐term outcomes to enhance interdisciplinary treatment strategies. These findings pave the way for improved care via a tailored approach to patients with both cancer and cardiovascular disease.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** gynecologic malignancies (MESH:D005833), acute myocardial infarction (MESH:D009203), cardiovascular complications (MESH:D002318), lung cancer (MESH:D008175), coagulopathies (MESH:D001778), infection (MESH:D007239), VHD (MESH:D006349), ischemic disease (MESH:D017202), AF (MESH:D001281), pulmonary disease (MESH:D008171), ischemic (MESH:D002545), thrombocytopenia (MESH:D013921), Ischemic Stroke (MESH:D002544), GI and GU malignancies (MESH:D009369), calcification (MESH:D002114), brain infarctions (MESH:D020520), DVT (MESH:D020246), vascular injury (MESH:D057772), metastatic disease (MESH:D000092182), cardioembolic stroke (MESH:D000083262), ASD (MESH:D001321), chronic kidney disease (MESH:D051436), hemorrhagic stroke (MESH:D000083302), hemorrhagic shock (MESH:D012771), blood loss (MESH:D016063), anemia (MESH:D000740), MV disease (MESH:D004194), inflammatory (MESH:D007249), fibrosis (MESH:D005355), prostate cancer (MESH:D011471), thrombosis (MESH:D013927), hematologic abnormalities (MESH:D006402), VTE (MESH:D054556), leukemia (MESH:D007938), atherosclerosis (MESH:D050197), coronary disease (MESH:D003327), stenosis (MESH:D003251), cardiotoxic (MESH:D066126), blood cancers (MESH:D019337), PFO (MESH:D054092), emboli (MESH:D020766), oncologic (MESH:D000072716), PE (MESH:D011655), cryptogenic stroke (MESH:D000083242), MR (MESH:D008944), bone marrow failure (MESH:D000080983), radiation (MESH:D011832), hemolysis (MESH:D006461), LAA occlusion (MESH:D059446), aortic valve disease (MESH:D000082862), embolic (MESH:D004617), left ventricular dysfunction (MESH:D018487), pleural effusions (MESH:D010996), congestive heart failure (MESH:D006333), AS (MESH:D001024), prostate, breast, lung, and renal cancers (MESH:D001943), Bleeding (MESH:D006470), thromboembolic (MESH:D013923), gastrointestinal malignancies (MESH:D005770), vascular complications (MESH:D003925)
- **Chemicals:** dalteparin (MESH:D017985), C (MESH:D002244), DOACs (-), warfarin (MESH:D014859), heparin (MESH:D006493), aspirin (MESH:D001241), rivaroxaban (MESH:D000069552), apixaban (MESH:C522181)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960413/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960413/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960413/full.md

---
Source: https://tomesphere.com/paper/PMC12960413